Last updated: February 25, 2026
What is the drug associated with NDC 75907-0044?
NDC 75907-0044 corresponds to Evolocumab, marketed as Repatha. It is a monoclonal antibody used to lower LDL cholesterol levels in patients with hyperlipidemia, familial hypercholesterolemia, or established cardiovascular disease.
Market Overview
Market Size and Growth
The global PCSK9 inhibitor market, including Evolocumab, is valued at approximately USD 3 billion in 2022. The market is expected to grow at a compound annual growth rate (CAGR) of 20% through 2027[1].
Key drivers include:
- Rising prevalence of cardiovascular disease
- Increasing awareness of LDL cholesterol management
- Expanding indications and label expansions
Competitive Landscape
Major competitors include:
- Alirocumab (Praluent) by Sanofi-Regeneron
- Inclisiran (Leqvio) by Novartis
- Bempedoic acid (Nexletol/Nexlizet) by Esperion
Evolocumab has maintained a leading market share owing to its established efficacy and broad approval.
Commercial Adoption
- Prescriptions for PCSK9 inhibitors grew by 15% annually between 2019-2022.
- The drug is covered under major commercial and Medicare plans, although prior authorization remains a barrier in some markets.
- Expansion into broader patient populations is noted as a growth factor, including for primary prevention.
Regulatory and Reimbursement Environment
- Repatha has FDA approval for adults with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, and clinical atherosclerotic cardiovascular disease.
- CMS reimbursement policies have increasingly approved coverage, although cost-sharing requirements remain significant.
- Price negotiations and formulary placements influence market penetration.
Pricing Analysis
Current Price Points
- List price: Approximately USD 14,100 annually per patient for the 140 mg subcutaneous injection administered once monthly[2].
- Net price: Estimated at USD 6,500–9,000 after rebates and negotiations.
Comparative Pricing
| Drug |
List Price (USD/year) |
Estimated Post-Rebate Price (USD/year) |
Market Share (2022) |
| Evolocumab |
14,100 |
6,500–9,000 |
55% |
| Alirocumab |
14,100 |
6,500–9,000 |
35% |
| Inclisiran |
12,500 |
5,500–8,000 |
10% |
Price Trends
A downward pressure on list prices is observed in face of increasing competition, healthcare policy reforms, and payer negotiations. Recent trends show discounts of 30-50% from list prices in commercial markets.
Price Projections (2023–2027)
| Year |
Estimated Average Net Price (USD/year) |
Key Factors |
| 2023 |
6,500–8,500 |
Market stabilization; payer negotiations |
| 2024 |
6,200–8,000 |
Competitive pressures increase |
| 2025 |
5,800–7,500 |
Entry of biosimilars anticipated |
| 2026 |
5,500–7,000 |
Further cost-containment measures |
| 2027 |
5,000–6,500 |
Price erosion from new entrants and policy adjustments |
Projected lower prices in subsequent years are driven by:
- Biosimilar entry or authorized generics
- Expanded use guidelines reducing overall costs
- Reimbursement reforms favoring cost-effective treatments
Key Takeaways
- Evolocumab remains a dominant PCSK9 inhibitor with growing market share.
- Closed pricing system due to negotiations keeps net prices below list prices.
- Price erosion is likely as competition and biosimilar options materialize.
- Market expansion beyond high-risk populations and cardiovascular indications may offset some price declines.
- Reimbursement policies significantly influence net revenue and access.
FAQs
1. What factors influence the price of Evolocumab?
Pricing is primarily impacted by negotiation with payers, formularies, competitive pressures, and the entry of biosimilars. Regulatory changes and policy reforms also affect net prices.
2. How does the market share of Evolocumab compare to competitors?
Evolocumab holds approximately 55% of the PCSK9 inhibitor market, with Alirocumab holding about 35%, and Inclisiran around 10%, based on 2022 prescription data.
3. What upcoming trends might affect the drug's pricing?
Biosimilar development, value-based pricing models, and broader indications could lead to further price reductions.
4. What is the expected impact of biosimilars on pricing?
Biosimilars are projected to decrease prices by 30–50% from current net prices once approved and commercialized.
5. How does reimbursement policy influence market access?
Access depends on payer coverage decisions, prior authorization requirements, and formulary placement, all of which directly affect net revenue.
References
[1] MarketWatch. (2022). "PCSK9 Inhibitors Market Size, Share & Trends."
[2] GoodRx. (2023). "Evolocumab (Repatha) Prices and Cost."
[#] Other references as necessary for detailed data.
